We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Refractory Bacteria Respond to Fecal Transplant

By HospiMedica International staff writers
Posted on 17 Nov 2011
Transplanting fecal matter with healthy bacteria into patients with refractory Clostridium difficile infections can lead to quick relief, according to a new study.

Researchers at Integris Baptist Medical Center (Oklahoma City, OK, USA) and Montefiore Medical Center (New York, NY, USA;) conducted a study that included 77 patients (mean age 65, 73% women) who underwent a colonoscopic fecal-microbiota transplant (FMT) at least three months previously for recurrent C. More...
difficile infection; 31 of the patients were hospitalized, homebound, or in a skilled nursing facility at the time the procedure was performed. The patients subsequently answered a 36-item questionnaire about the results of the transplant.

The researchers found that FMT was successful in 70 out of 77 patients (91%) who were on average elderly, debilitated, and had undergone multiple failed treatments, including antibiotic and probiotic therapies. The average duration of illness for these patients was 11 months, but after the procedure patients continued to improve and did not have a recurrence of C. difficile infection during the follow-up period. In six of the remaining seven patients, a single two-week course of vancomycin or a two-week vancomycin course plus one further FMT resulted in a 98% cure rate. The study was presented at the annual meeting of the American College of Gastroenterology, held during October 2011 in Washington DC (USA).

“Patients with recurrent C. difficile infection had a totally different population in their stool than normal people, characterized by a marked decrease in the diversity of species present,” said lead author and study presenter Mark Mellow, MD, of the Integris Baptist Medical Center. “Therefore, it would make sense that if you performed a massive bacterial replacement, that might very well reverse that condition and allow for a cure in people who were otherwise not curable.”

Clostridium difficile is a major cause of morbidity and increasing health care costs among hospitalized patients, causing infections that lead to diarrhea and is most often related to antibiotic use during medical treatment. C. difficile is especially dangerous for patients with weakened immune systems such as the elderly and those with Inflammatory Bowel Disease (IBD). Therapies for this difficult-to-treat subpopulation include antibiotics, probiotics, toxin-binding medications, active vaccination, intravenous immunoglobon, and FMT.

Related Links:

Integris Baptist Medical Center
Montefiore Medical Center




New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Fetal Monitor
BT-380
New
Digital Radiography System (Ceiling Free)
Digix CF Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Six-month FlexPulse IDE data show positive outcomes with Abbott’s TactiFlex Duo catheter, confirming safety and efficacy seen in the CE Mark study for complex AFib (photo courtesy of Abbott)

Dual-Energy Ablation and Conduction System Pacing Show Positive Early Outcomes

Atrial fibrillation and other arrhythmias are common in both hospitalized and ambulatory patients, often complicating hemodynamic stability, stroke prevention, and perioperative care. Within this context,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.